Tabula Rasa HealthCare Inc (NASDAQ:TRHC) President Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction on Monday, November 19th. The shares were sold at an average price of $61.68, for a total value of $493,440.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of TRHC opened at $65.33 on Friday. The company has a current ratio of 0.49, a quick ratio of 0.46 and a debt-to-equity ratio of 0.28. Tabula Rasa HealthCare Inc has a 1 year low of $27.25 and a 1 year high of $91.16. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -1,634.50, a P/E/G ratio of 6.04 and a beta of 2.58.
Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its earnings results on Tuesday, November 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.07. Tabula Rasa HealthCare had a positive return on equity of 7.63% and a negative net margin of 13.49%. The firm had revenue of $54.42 million for the quarter, compared to analysts’ expectations of $52.87 million. During the same quarter last year, the business earned $0.08 earnings per share. The company’s revenue was up 66.3% compared to the same quarter last year. As a group, equities analysts predict that Tabula Rasa HealthCare Inc will post 0.42 earnings per share for the current year.
A number of brokerages have recently weighed in on TRHC. Cantor Fitzgerald restated a “buy” rating and issued a $99.00 target price on shares of Tabula Rasa HealthCare in a research note on Tuesday, November 6th. Zacks Investment Research upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a $74.00 price objective for the company in a research report on Saturday, August 11th. Citigroup lifted their price objective on Tabula Rasa HealthCare from $57.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Chardan Capital lifted their price objective on Tabula Rasa HealthCare from $77.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Finally, BidaskClub upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research report on Tuesday, November 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $81.60.
TRADEMARK VIOLATION NOTICE: This news story was published by WKRB News and is the property of of WKRB News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.wkrb13.com/2018/11/24/insider-selling-tabula-rasa-healthcare-inc-trhc-president-sells-493440-00-in-stock.html.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Read More: Stock Symbols and CUSIP Explained
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.